The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Exposure of Adolescent Rats to Oral Methylphenidate: Preferential Effects on Extracellular Norepinephrine and Absence of Sensitization and Cross-Sensitization to Methamphetamine
Open accessAbstract
Methylphenidate (MP) (ritalin) is widely used in the treatment of children and adolescents with attention deficit hyperactivity disorder, but little is known about therapeutic mechanisms or about possible consequences of long-term exposure. To more closely simulate the clinical use of the drug, we orally administered MP to adolescent rats during the dark-active phase of the circadian cycle at doses (0.75-3.0 mg/kg) below threshold for locomotor activation. We found that doses in this range increased extracellular norepinephrine in hippocampus without affecting dopamine in nucleus accumbens. These results suggest that norepinephrine systems may play an important role in the therapeutic action of this drug. To examine one potential consequence of long-term exposure to MP, i.e., the development of locomotor sensitization, an adaptational change that has been implicated in drug abuse liability, animals received three daily oral administrations of these doses of MP for up to 4 weeks through adolescence. The animals were then challenged with methamphetamine (0.5 mg/kg). We found that the behavioral response to MP did not change during the course of chronic treatment and that MP-pretreated animals did not exhibit a sensitized locomotor response to the methamphetamine challenge. We propose that, to the extent that this treatment protocol more closely reflects clinical exposure patterns, the relative insensitivity of accumbens dopamine to the acute administration of these MP doses, and the corresponding absence of evidence for the development of locomotor sensitization, supports one clinical view that there is little abuse liability associated with low dose, long-term MP treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These lower doses in rats improve PFC attention and working memory function, enhance PFC neuronal response, and reduce locomotor hyperactivity in juveniles (Arnsten and Dudley, 2005; Berridge et al., 2006; Kuczenski and Segal, 2002).”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Kuczenski and Segal, 2002
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When administered in appropriate doses, these medications improve PFC function both in healthy human subjects (Elliott et al., 1997) and in animals (Arnsten and Dudley, 2005), including the reduction of locomotor hyperactivity in juvenile rats (Kuczenski and Segal, 2002).”
From Catecholamine influences on prefrontal cortical function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders (2011) · cites this paper as Kuczenski and Segal, 2002
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neural basis of drug craving: An incentive-sensitization theory of addiction
Robinson, T. (1993) · Brain Research Reviews · doi:10.1016/0165-0173(93)90013-p · Cited by 7,346
Robinson, T. G., & BECKER, J. (1986) · Brain Research · doi:10.1016/s0006-8993(86)80193-7 · Cited by 2,108
Robinson, T. E., & Becker, J. B. (1986) · Brain Research Reviews · doi:10.1016/0165-0173(86)90002-0 · Cited by 1,796
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498
Vanderschuren, L. J. M. J., & Kalivas, P. W. (2000) · Psychopharmacology · doi:10.1007/s002130000493 · Cited by 1,360
A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants
Pierce, R. C., & Kalivas, P. W. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00021-0 · Cited by 1,239
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
D1 receptors in prefrontal cells and circuits
Goldman-Rakic, P. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00045-4 · Cited by 822
Volkow, N. D., Wang, G.-J., Fowler, J. S., Logan, J., Gerasimov, M., Maynard, L., Ding, Y.-S., Gatley, S. J., Gifford, A., & Franceschi, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-j0001.2001 · Cited by 770
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Kuczenski, R., & Segal, D. S. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052032.x · Cited by 623
Self-citationMehta, M. A., Owen, A. M., Sahakian, B. J., Mavaddat, N., Pickard, J. D., & Robbins, T. W. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-06-j0004.2000 · Cited by 608 · cited 8×
“However, a minimal effect of low doses of MP on dopamine in nucleus accumbens does not preclude a more substantial effect in other dopamine projection sites, particularly in prefrontal cortex, which appears to play a particularly important role in processes that have been implicated in ADHD (Hale et al., 2000; Mehta e…”
BackgroundInfluentialScahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., Shepherd, E., Arnsten, A. F. T., Cohen, D. J., & Leckman, J. F. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.7.1067 · Cited by 588
Sesack, S. R., Hawrylak, V. A., Matus, C., Guido, M. A., & Levey, A. I. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-07-02697.1998 · Cited by 586
Methylphenidate: Its Pharmacology and Uses
Challman, T. D., & Lipsky, J. J. (2000) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)64618-1 · Cited by 568
Salamone, J. D., Cousins, M. S., & Snyder, B. J. (1997) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(96)00017-6 · Cited by 522
Robinson, T. E., & Whishaw, I. Q. (1988) · Brain Research · doi:10.1016/0006-8993(88)91560-0 · Cited by 520
Kalivas, P., & Duffy, P. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-01-00266.1993 · Cited by 516
Attention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
Biederman, J., & Spencer, T. J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00192-4 · Cited by 515
Neuroadaptations involved in amphetamine and cocaine addiction
White, F. J., & Kalivas, P. W. (1998) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00072-6 · Cited by 513
Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder
Biederman, J., Wilens, T., Mick, E., Spencer, T., & Faraone, S. V. (1999) · Pediatrics · doi:10.1542/peds.104.2.e20 · Cited by 493
Kalivas, P., & Duffy, P. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-01-00276.1993 · Cited by 402
Chemical neuromodulation of frontal-executive functions in humans and other animals
Robbins, T. W. (2000) · Experimental Brain Research · doi:10.1007/s002210000407 · Cited by 399
Kuczenski, R. T., & Segal, D. (1989) · Journal of Neuroscience · doi:10.1523/jneurosci.09-06-02051.1989 · Cited by 398
Self-citationMan versus Beast: Pharmacokinetic Scaling in Mammals
Mordenti, J. J. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751104 · Cited by 387
Laviola, G., Adriani, W., Terranova, M. L., & Gerra, G. (1999) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00032-9 · Cited by 345
Paulson, P. E., & Robinson, T. E. (1995) · Synapse · doi:10.1002/syn.890190108 · Cited by 341
Ferguson, J. H. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200002000-00018 · Cited by 321
Synaptic regulation of mesocorticolimbic dopamine neurons
White, F. J. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.19.030196.002201 · Cited by 289
Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder
Cipkala-Gaffin, J. A. (1998) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.1998.tb01010.x · Cited by 275
Kuczenski, R. T., & Segal, D. S. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38829-9 · Cited by 267
Self-citationAltered responsiveness to cocaine in rats exposed to methylphenidate during development
Andersen, S. L., Arvanitogiannis, A., Pliakas, A. M., LeBlanc, C., & Carlezon, W. A. (2002) · Nature Neuroscience · doi:10.1038/nn777 · Cited by 259
Brandon, C. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00281-0 · Cited by 259
Gerasimov, M. R., Franceschi, M., Volkow, N. D., Gifford, A. J., Gatley, S. J., Marsteller, D. A., Molina, P. E., & Dewey, S. L. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38868-8 · Cited by 253
Pharmacokinetics of methylphenidate in man, rat and monkey.
Wargin, W. A., Patrick, K. S., Kilts, C. D., Gualtieri, C. T., Ellington, K. R., Mueller, R. A., Kraemer, G. W., & Breese, G. R. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21542-7 · Cited by 223
Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., Williams, L., Shoulson, I., & Wigal, S. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70038-x · Cited by 216
Moll, G. H., Heinrich, H., Trott, G., Wirth, S., & Rothenberger, A. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00980-0 · Cited by 203
Taylor, F. B., & Russo, J. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00015 · Cited by 189
Stimulant Drugs and ADHD: Basic and Clinical Neuroscience
Durant, N. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1959-a · Cited by 179
Segal, D. S., & Kuczenski, R. (1987) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39192-5 · Cited by 177
Self-citationSwanson, J. M., & Volkow, N. D. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00433-8 · Cited by 173
Tanda, G., Pontieri, F. E., Frau, R., & Chiara, G. D. (1997) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1997.tb01375.x · Cited by 168
VITIELLO, B., SEVERE, J. B., GREENHILL, L. L., ARNOLD, L. E., ABIKOFF, H. B., BUKSTEIN, O. G., ELLIOTT, G. R., HECHTMAN, L., JENSEN, P. S., HINSHAW, S. P., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00013 · Cited by 163
Strakowski, S. M., & Sax, K. W. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00454-x · Cited by 160
Patrick, K. S., & Markowitz, J. S. (1997) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/(sici)1099-1077(199711/12)12:6 · Cited by 132
Szabo, S. T., & Blier, P. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01583.x · Cited by 125
Florin, S. M., Kuczenski, R. T., & Segal, D. S. (1994) · Brain Research · doi:10.1016/0006-8993(94)91570-9 · Cited by 124
Self-citationSensitization to locomotor effects of methylphenidate in the rat
Gaytan, O., al-Rahim, S., Swann, A. C., & Dafny, N. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00598-5 · Cited by 119
Wayment, H., Schenk, J. O., & Sorg, B. A. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-01-00035.2001 · Cited by 118
Diurnal differences in sensitization to methylphenidate
Gaytan, O., Yang, P. B., Swann, A. C., & Dafny, N. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02117-x · Cited by 107
Shaywitz, S. E., Hunt, R. D., Jatlow, P. L., Cohen, D. J., Young, J. G., Pierce, R. N., Anderson, G., & Shaywitz, B. A. (1982) · PEDIATRICS · doi:10.1542/peds.69.6.688 · Cited by 104
New developments in impulsivity
Hollander, E., & Evers, M. M. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06114-1 · Cited by 79
Garland, E. J. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200410 · Cited by 77
Human Response to Repeated Low-Dose d-Amphetamine: Evidence for Behavioral Enhancement and Tolerance
Strakowski, S. M. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00253-6 · Cited by 71
McNamara, C., Davidson, E. S., & Schenk, S. (1993) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(93)90532-x · Cited by 68
Evason, D. J., Claydon, M. A., & Gordon, D. B. (2000) · Rapid Communications in Mass Spectrometry · doi:10.1002/(sici)1097-0231(20000430)14:8 · Cited by 63
Safer, D. J., & Allen, R. P. (1989) · The Journal of Pediatrics · doi:10.1016/s0022-3476(89)80759-0 · Cited by 59
Regional norepinephrine response to amphetamine using dialysis: Comparison with caudate dopamine
Kuczenski, R. T., & Segal, D. S. (1992) · Synapse · doi:10.1002/syn.890110210 · Cited by 57
Self-citationDiurnal differences in amphetamine sensitization
Gaytan, O., Lewis, C., Swann, A. C., & Dafny, N. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00243-5 · Cited by 56
Methylphenidate: diurnal effects on locomotor and stereotypic behavior in the rat
Gaytan, O., Ghelani, D., Martin, S., Swann, A. C., & Dafny, N. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00880-9 · Cited by 55
Enhanced behavioral response to repeated d-amphetamine and personality traits in humans
Sax, K. W., & Strakowski, S. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00168-1 · Cited by 51
Distribution of methylphenidate and p-hydroxymethylphenidate in rats.
Patrick, K. S., Ellington, K. R., & Breese, G. R. (1984) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21595-6 · Cited by 50
Dopaminergic and Noradrenergic Influences on Cognitive Functions Mediated by Prefrontal Cortex
Arnsten, A. F. T. (2000) · Oxford University Press eBooks · doi:10.1093/oso/9780195133714.003.0008 · Cited by 46
Medication for Children With Attentional Disorders
Committee on Children, & Disabilities and Committee on Drugs (1996) · PEDIATRICS · doi:10.1542/peds.98.2.301 · Cited by 44
(1998) · PubMed · Cited by 41
Aoyama, T., Kotaki, H., & Iga, T. (1990) · Journal of Pharmacobio-Dynamics · doi:10.1248/bpb1978.13.647 · Cited by 36
Dose-related effects of MK-801 on acute and chronic methylphenidate administration
Sripada, S., Gaytan, O., al-Rahim, S., Swann, A. C., & Dafny, N. (1998) · Brain Research · doi:10.1016/s0006-8993(98)01035-x · Cited by 31
Synaptic Regulation of Mesocorticolimbic Dopamine Neurons
White, F. J. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.19.1.405 · Cited by 30
Thai, D. L., Yurasits, L. N., Rudolph, G. R., & Perel, J. M. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15300-7 · Cited by 29
Chemical neuromodulation of frontal-executive functions in humans and other animals
Robbins, T. W. (2000) · Springer eBooks · doi:10.1007/978-3-642-59794-7_14 · Cited by 27
Pharmacotherapy of attention‐deficit/hyperactivity disorder reduces risk for substance use disorder.
Nathwani, A. (2000) · Ambulatory Child Health · doi:10.1046/j.1467-0658.2000.0062i.x · Cited by 20
Shaywitz, S. E., Hunt, R. D., Jatlow, P. L., Cohen, D. J., Young, J. G., Pierce, R. N., Anderson, G., & Shaywitz, B. A. (1982) · Journal of the American Academy of Child Psychiatry · doi:10.1097/00004583-198211000-00025 · Cited by 5
Research works printed but not linked: 3
- Sagvolden T (2001) The spontaneously hypertensive rat as a model for ADHD. In: Stimulant drugs and ADHD: basic and clinical neuro- science (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 221-237. New York: Oxford UP.
- Solanto MV, Arnsten AFT, Castellanos FX (2001) The neuroscience of stimulant drugs in ADHD. In: Stimulant drugs and ADHD: basic and clinical neuroscience (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 355-379. New York: Oxford UP.
- Taylor JR, Jentsch JD (2001) Stimulant effects on striatal and cortical dopamine systems involved in reward-related behavior and impulsivity: implications for ADHD. In: Stimulant drugs and ADHD: basic and clinical neuroscience (Solanto MV, Arnsten AFT, Castellanos FX, eds), pp 104 -133. New York: Oxford UP.
Cited by
Sorted by citations
Berridge, C. W., & Waterhouse, B. D. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00143-7 · Cited by 2,529
Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions
Arnsten, A. F. T., & Li, B.-M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.08.019 · Cited by 948
Berridge, C. W., Devilbiss, D. M., Andrzejewski, M. E., Arnsten, A. F. T., Kelley, A. E., Schmeichel, B., Hamilton, C., & Spencer, R. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.022 · Cited by 617
Stimulants: Therapeutic Actions in ADHD
Arnsten, A. F. T. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301164 · Cited by 473
Arnsten, A. F. T., & Pliszka, S. R. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.01.020 · Cited by 383
Metadata
- Authors
- Kuczenski, R., & Segal, D. S.
- Affiliations
- University of California San Diego (US)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2002-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 7264-7271
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6757883
- OpenAlex
- W2159875740
- Cited by
- 316
- References
- 75
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 6 · 2018: 12 · 2017: 12 · 2016: 10 · 2015: 28 · 2014: 16 · 2013: 21 · 2012: 21
- FWCI
- 4.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuroscience (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of California, San Diego
- National Institute on Drug Abuse (R01DA001568)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- methylphenidate, adolescent rats, hippocampus, nucleus accumbens dopamine, locomotor sensitization, cross-sensitization, abuse liability, attention deficit hyperactivity disorder, long-term drug exposure
- MeSH terms
- Administration, Oral, Age Factors, Animals, Behavior, Animal, Dopamine, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Interactions, Extracellular Space, Hippocampus, Male, Methamphetamine, Methylphenidate, Motor Activity, Norepinephrine, Nucleus Accumbens, Time, Rats, Sprague-Dawley, Microdialysis, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review